Bio-Rad Laboratories, Inc. (BIO) fair value analysis
S&P 500 · Updated 2026-09-07
Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products, clinical diagnostics products, and related laboratory equipment. The company operates globally across North America, Europe, and other international markets, serving research institutions, clinical laboratories, and healthcare providers.
Forward Fair Value verdict
OvervaluedBased on TickrTrends' weekly Forward Fair Value model, BIO is trading at a 10–25% premium to estimated fair value.
BIO currently ranks #88 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.
- Last price
- $330.01
- Sector
- Healthcare
- 12-month range
- $256.55–$380.96
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- B
- Leverage
- Low
- Margin trend
- Contracting
- Revenue growth
- Declining
- RSI zone
- Neutral
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
What our data shows for BIO
- Our model validated 17 trailing price-to-earnings windows for BIO, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $256.55–$380.96.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BIO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent BIO news
TickrTrends' derived news-sentiment signal for BIO is currently leaning positive, computed from recent coverage.
- Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? (insidermonkey.com, 2026-08-14)
TickrTrends take: Bio-Rad Laboratories operates in a cyclical bioprocessing market where demand depends heavily on broader industry trends affecting companies like Danaher Corporation. With TickrTrends currently assessing BIO as overvalued, investors focused on valuation metrics should monitor whether any recovery in Danaher's bioprocessing segment translates into margin expansion or revenue growth sufficient to justify current pricing. A valuation-conscious observer would need to see whether improved industry conditions can narrow the gap between BIO's market price and its intrinsic value metrics. - Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary (finance.yahoo.com, 2026-08-05)
TickrTrends take: # Bio-Rad Laboratories, Inc. Stock Research Bio-Rad Laboratories operates in the Healthcare sector, where valuations can reflect both near-term earnings performance and long-term growth expectations. Given TickrTrends' current assessment that BIO is overvalued, investors tracking the company's financial health should monitor whether Q2 2026 results demonstrate sufficient earnings growth and operational efficiency to justify current pricing. The gap between market valuation and underlying fundamentals becomes particularly relevant in Healthcare, where regulatory developments and competitive dynamics can rapidly shift investor sentiment and warrant recalibration of valuation multiples.
What people are saying
Follow the BIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for BIO in the Healthcare sector have shifted this week. The DCF cross-check band moved from showing no clear verdict to indicating an overvalued state, while the RSI zone improved from overbought to neutral territory. The current valuation verdict remains overvalued.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BIO stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BIO is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is BIO's TickrTrends verdict?
BIO's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does BIO compare to other Healthcare stocks?
BIO ranks #88 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is BIO overbought or oversold?
BIO's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
BIO vs ABBV · BIO vs BIIB · BIO vs BVS · BIO vs CVS · BIO vs INMD